University of California

University of South Florida

Rigel Pharmaceuticals, Incorporated

Kyle Defrees

Somasekhar Bhamidipati

Vanessa Taylor

Simon Shaw

Adam Renslo

Yu Chen

Priyadarshini Jaishankar

Xiujun Zhang

Orville Antonio Pemberton

Nicholas Joseph Torelli

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Heterocyclic RIP1 kinase inhibitors

The present disclosure provides compositions including a beta-lactamase inhibitor, pharmaceutical compositions including a beta-lactamase inhibitor, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

Compositions, methods of use, and methods of treatment

Growing community of inventors

San Francisco, CA, United States of America

Kyle Defrees